about
Pearson syndrome in an infant heterozygous for C282Y allele of HFE genePandemic influenza A 2009 (H1N1) vaccination in high risk children with chronic renal diseases: acceptance and perceptions.Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management.A case of immune thrombocytopenic purpura after influenza vaccination: consequence or coincidence?Natural History, Pathogenesis, and Treatment of Evans Syndrome in Children.Immunotherapy in patients with systemic mycoses: a promising adjunct.Granulocyte colony-stimulating factor and other cytokines in antifungal therapy.Outbreak of bloodstream infections because of Serratia marcescens in a pediatric department.Host genetics and opportunistic fungal infections.Simultaneous changes in serum HMGB1 and IFN-α levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE. New therapeutic options?Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation.Novel biomarkers for the assessment of paediatric systemic lupus erythematosus nephritis.Antibiotics-induced acute interstitial nephritis in 6 children.Assessment of IgE-mediated food allergies in children with atopic dermatitis.Clinical picture and treatment of 2212 patients with common variable immunodeficiency.Mannose binding lectin and ficolin-2 polymorphisms are associated with increased risk for bacterial infections in children with B acute lymphoblastic leukemia.The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis.Hereditary angioedema in Greece: the first results of the greek hereditary angioedema registry.Human immunodeficiency virus infection and cutaneous aspergillosis.Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.Increased osteoclastic activity as shown by increased sRANK-L/OPG ratio in boys with hemophilia.Comparative study of dual energy X-ray absorptiometry and quantitative ultrasonography with the use of biochemical markers of bone turnover in boys with haemophilia.The portrait of Familial Mediterranean Fever in N. Greek pediatric patients: a 30-year experience.Filamentous fungi in a tertiary care hospital: environmental surveillance and susceptibility to antifungal drugs.Validation study of the pediatric allergic rhinitis quality of life questionnaire.SIAE Rare Variants in Juvenile Idiopathic Arthritis and Primary Antibody Deficiencies.Brittle Hair, Photosensitivity, Brain Hypomyelination and Immunodeficiency: Clues to Trichothiodystrophy.Frequency, clinical characteristics, and genotype distribution of rotavirus gastroenteritis in Greece (2007-2008).Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatmentFungal Colonization in the Neonatal Intensive Care Unit: Risk Factors, Drug Susceptibility, and Association with Invasive Fungal InfectionsTransforming growth factor-?1 in the urine of young children with urinary tract infectionGemella morbillorum endocarditis in a child
P50
Q28248388-01FC2BD5-E6FC-4A94-8020-6C80B1BDF173Q30394647-9532FEA7-D45E-4751-8FD6-F54EC55B7960Q33387951-F578EB3C-FFAD-45E5-9B79-8DA7F1ED7271Q33390066-8DE8D9EE-DE46-4FB3-B6AF-5011551958CBQ33443018-C06FCF59-8B8D-4169-8D36-5A6D9B36B60AQ34299319-EDF33A57-C138-419E-92A6-D8D33D81C079Q34348186-4CAA3C5D-5816-48AD-846F-7771025A85E9Q37920291-61B09316-7CE6-4C0C-973F-AAE6252AEAB0Q38255966-71126084-7080-4AF1-A82F-6629F2EAF125Q39277686-E02DB622-DA8A-4B23-BADF-89178769C5E2Q39327528-4D04E58C-5F39-46C4-9A6C-188801FECB2CQ40432262-49EE42B0-AC0B-4632-B4AD-F8D0A8B51FA0Q40479773-37D71FCA-94D6-4B69-9401-56727F6FF55BQ40549860-14A93700-E87A-4BE4-964D-63317A385483Q42226474-3919AF0E-FEBD-450B-B50A-22F6015926D5Q42231801-7CA094C4-A75A-4490-8258-E605FC6DAD72Q43063060-748F8F9D-56EB-488F-82BA-C9DC987D6F41Q44083903-D5932403-1B7A-424B-ACAE-6514B3912F1DQ45743723-D58BE57C-A37D-4F69-99A5-4E50288CD567Q45748588-3CC216FA-988C-488E-85BF-F2F307809FBBQ45856397-6F1EE5ED-07CC-44BE-87CE-F5D70E8CCDE0Q45863433-42423675-ABAD-4433-88F6-3F4FC50094B2Q46361632-58F32D12-0254-4ABD-9AA1-828AD583CE6DQ46362922-862AB5D3-A119-49D9-A0CA-6C047B1F0E64Q47791499-05E79317-B1C5-447F-A2EB-4E3A4D904355Q48357629-CF9C48CA-EE8B-4934-A3E2-2D2E55C9033BQ48595966-9465C386-D1BE-4CE4-94A1-F04A0C8355D0Q54400326-FFEEC7A3-E2D4-4DC6-8B86-678661272E51Q61895915-07AE6B43-2377-4E13-A62A-A34F9BAA9CC5Q61895931-9A216A85-B477-4720-BE67-DC79E3CEBD9EQ61895935-B3DFEB20-56BB-46D6-8367-E4810FC1C521Q61895938-4D0CC373-E633-4DF0-AFBC-8BB156D6F5D3
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Evangelia Farmaki
@ast
Evangelia Farmaki
@en
Evangelia Farmaki
@es
Evangelia Farmaki
@nl
Evangelia Farmaki
@sl
type
label
Evangelia Farmaki
@ast
Evangelia Farmaki
@en
Evangelia Farmaki
@es
Evangelia Farmaki
@nl
Evangelia Farmaki
@sl
prefLabel
Evangelia Farmaki
@ast
Evangelia Farmaki
@en
Evangelia Farmaki
@es
Evangelia Farmaki
@nl
Evangelia Farmaki
@sl
P106
P21
P31
P496
0000-0002-5132-8255
P569
2000-01-01T00:00:00Z